Navigation Links
Business of drug development on verge of great change
Date:4/1/2008

Significant changes to drug discovery and the pharmaceutical industry currently underway will increase in the next five to 10 years, according to a top researcher at the National Institutes of Health (NIH) who is helping transform the business of drug research and development.

According to Christopher Austin, M.D., director of the NIH Chemical Genomics Center (NCGC), both industry and academia welcome more cooperation in drug discovery to secure more efficient results for less financial burden than if they operate independently. The increased participation of the public sector in therapeutics development is a trend that will be good for industry, academia, scientific discovery and the public at large, says Dr. Austin.

These collaborative efforts have been facilitated by researchers moving from industry to academia to help close the gap that exists between basic early stage research and the identification of viable drug candidates for a range of diseases, particularly those that are less prevalent or for which the targets are less well validated. The hope is that better drugs to treat more diseases will be developed faster and less expensively than ever before.

Not only is Dr. Austin a scientist who wants his work to improve the lives of people affected by disease, he also is a former pharmaceutical industry researcher who understands the business of drug development, having previously worked at Merck & Co. for a number of years. Hes observed that industry scientists are constrained in the scope of targets and diseases they study by commercial regulations imperatives which do not exist in the public sector. The work we do at the NCGC is complementary to what industry does we work on the 90% of new targets and diseases that industry doesnt, and we make our data publicly available so all researchers, public and private, can use it to advance drug discovery.

Marcie Glicksman, Ph.D., senior director of lead discovery, laboratory of drug discovery at the Harvard NeuroDiscovery Center and one of several co-presenters at the SBS meeting, also came from industry and has high hopes for the increased collaboration between Big Pharma and academia in drug discovery. At Harvard, our mission is to develop new therapeutics for diseases with no disease modifying treatments such as Parkinsons and Alzheimers, or orphan diseases such as Huntingtons and Amyotrophic Lateral Sclerosis (Lou Gehrigs), she states. There are smaller numbers of patients affected by orphan diseases -- treatments for them are not considered billion dollar drugs, so they are much harder to develop in industry.

Like Dr. Austin, Dr. Glicksman says its simply too expensive for industry to conduct this early stage research, and that is why the academic centers are so vital to the future of drug discovery for diseases that industry cant address on its own.

Dr. Austin and Dr. Glicksman will speak at a session on this topic at the 14th Annual Conference & Exhibition of the Society for Biomolecular Sciences (SBS) April 6-10 at Americas Center in St. Louis.


'/>"/>

Contact: Jennifer Bender
jbender@environics-usa.com
203-325-8772 x18
Society for Biomolecular Sciences
Source:Eurekalert

Related medicine news :

1. Underwriters Laboratories Management System Registration Business to Merge With Germanys DQS
2. Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum
3. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
6. Barr Announces Reorganization of Senior Management, Business Functions
7. Small Business Health Care Survey Points to Need for Reform
8. Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
9. Caring.com Adds Vice President of Business Development
10. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
11. Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor ... Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday ... This will be the first Fisher House in Nevada, and will provide free lodging ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... ... Donor Network West, the organ procurement organization that heals lives through organ ... Regional Medical Center. Under the collaboration, the first of its kind, specific organ donors ... certain time frame for donor families for the recovery of organs. , Organ ...
(Date:2/12/2016)... ... 12, 2016 , ... J Thomas & Associates Insurance Agency, ... to act as Agents of Change in the community, announces a new partnership ... to fulfill immediate needs and help them move into permanent housing. Donations to ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
Breaking Medicine Technology: